| Funding agency |
Japan Agency for Medical Research and Development |
| Application year |
2021 |
| Call for applications |
既に作成済みのプロトコル（又はプロトコル骨子）に基づいて実施する医薬品に関する臨床研究・医師主導治験の推進（ステップ2）②医師主導治験（新有効成分含有医薬品） |
| Research field |
（Life Science）
Neuroscience-general、Anatomyandhistopathologyofnervoussystem、Functionofnervoussystem、Pharmacology、Clinicalpharmacy、Parasitology、Bacteriology、Virology、Immunology、Tumorbiology、Tumordiagnosticsandtherapeutics、Basicbrainsciences、Cognitiveandbrainscience、Pathophysiologicneuroscience、Generalinternalmedicine、Neurology、Psychiatry、Radiologicalsciences、Embryonicmedicineandpediatrics、Gastroenterology、Cardiology、Respiratorymedicine、Nephrology、Dermatology、Hematologyandmedicaloncology、Connectivetissuediseaseandallergy、Infectiousdiseasemedicine、Metabolismandendocrinology、Generalsurgeryandpediatricsurgery、Digestivesurgery、Cardiovascularsurgery、Respiratorysurgery、Anesthesiology、Emergencymedicine、Neurosurgery、Orthopedics、Urology、Obstetricsandgynecology、Otorhinolaryngology、Ophthalmology、Plasticandreconstructivesurgery、Oralbiologicalscience、Oralpathobiologicalscience、Conservativedentistry、Regenerativedentistryanddentalengineering
|
| Keyword |
医薬品 |
|
臨床研究 |
|
医師主導治験 |
|
臨床POC |
|
薬事承認 |
|
企業導出 |
|
ARO |
| Acceptable research periods (minimum/maximum) |
(the shortest) 1year (longest) 4year |
| Application period |
2020/11/12 12:00 ～ 2020/12/09 15:00 |
| Project category |
Contract research
|
| Target category |
Corporation（including industry, foundation and association）
、
University
、
Researcher・Research team
|
| Prospective cost restrictions |
Prospective cost restrictions |
(the lower limit)--.--(thousand yen) - (the upper limit) 400,000(thousand yen) |
| Indirect costs(maximum amount) |
Maximum30% of direct costs |
| Recommissionfee/jointresearch costs |
0(thousand yen) |
| URL of guidelines of call for applications |
臨床研究・治験推進研究事業令和3年度1次公募要領
|
| URL of past adoption statuses |
令和2年度 「臨床研究・治験推進研究事業（1次公募）」の採択課題について
|
Download
